ESMO 2026 | Adaptive NK cells to improve treatment response in advanced UC
Bérengère Salomé, PharmD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the potential for inducing adaptive NK cells in cancers other than BCG-treated non-muscle invasive bladder cancer, highlighting promise in patients with advanced urothelial carcinoma (UC) receiving combination treatment with enfortumab vedotin and pembrolizumab. This strategy may provide insights into improving treatment responses for these patients, and potentially for other cancer types as well. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
